trending Market Intelligence /marketintelligence/en/news-insights/trending/uxvhtmrrsmm2pkcuzpyr4q2 content esgSubNav
In This List

Akebia Therapeutics plans $85M common stock offering

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Akebia Therapeutics plans $85M common stock offering

Akebia Therapeutics Inc. plans to sell $85 million of its common shares in an underwritten public offering.

The company also plans to give the underwriter an option to buy up to an additional $12.8 million of shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, including pre-commercial planning activities, and the remainder for working capital, business development and other general corporate purposes.

Morgan Stanley is acting as sole book-running manager for the offering.